BACKGROUND: While olfactory deficits have been reported in schizophrenia and youths at-risk for psychosis, few studies have linked these deficits to current pathophysiological models of the illness. There is evidence that disrupted cyclic adenosine 3',5'-monophosphate (cAMP) signaling may contribute to schizophrenia pathology. As cAMP mediates olfactory signal transduction, the degree to which this disruption could manifest in olfactory impairment was ascertained. Odor-detection thresholds to two odorants that differ in the degree to which they activate intracellular cAMP were assessed in clinical risk and low-risk participants. METHOD: Birhinal assessments of odor-detection threshold sensitivity to lyral and citralva were acquired in youths experiencing prodromal symptoms (n=17) and controls at low risk for developing psychosis (n=15). Citralva and lyral are odorants that differ in cAMP activation; citralva is a strong cAMP activator and lyral is a weak cAMP activator. RESULTS: The overall group-by-odor interaction was statistically significant. At-risk youths showed significantly reduced odor detection thresholds for lyral, but showed intact detection thresholds for citralva. This odor-specific threshold deficit was uncorrelated with deficits in odor identification or discrimination, which were also present. ROC curve analysis revealed that olfactory performance correctly classified at-risk and low-risk youths with greater than 97% accuracy. CONCLUSIONS: This study extends prior findings of an odor-specific hyposmia implicating cAMP-mediated signal transduction in schizophrenia and unaffected first-degree relatives to include youths at clinical risk for developing the disorder. These results suggest that dysregulation of cAMP signaling may be present during the psychosis prodrome.
BACKGROUND: While olfactory deficits have been reported in schizophrenia and youths at-risk for psychosis, few studies have linked these deficits to current pathophysiological models of the illness. There is evidence that disrupted cyclic adenosine 3',5'-monophosphate (cAMP) signaling may contribute to schizophrenia pathology. As cAMP mediates olfactory signal transduction, the degree to which this disruption could manifest in olfactory impairment was ascertained. Odor-detection thresholds to two odorants that differ in the degree to which they activate intracellular cAMP were assessed in clinical risk and low-risk participants. METHOD: Birhinal assessments of odor-detection threshold sensitivity to lyral and citralva were acquired in youths experiencing prodromal symptoms (n=17) and controls at low risk for developing psychosis (n=15). Citralva and lyral are odorants that differ in cAMP activation; citralva is a strong cAMP activator and lyral is a weak cAMP activator. RESULTS: The overall group-by-odor interaction was statistically significant. At-risk youths showed significantly reduced odor detection thresholds for lyral, but showed intact detection thresholds for citralva. This odor-specific threshold deficit was uncorrelated with deficits in odor identification or discrimination, which were also present. ROC curve analysis revealed that olfactory performance correctly classified at-risk and low-risk youths with greater than 97% accuracy. CONCLUSIONS: This study extends prior findings of an odor-specific hyposmia implicating cAMP-mediated signal transduction in schizophrenia and unaffected first-degree relatives to include youths at clinical risk for developing the disorder. These results suggest that dysregulation of cAMP signaling may be present during the psychosis prodrome.
Authors: P A Thomson; N R Wray; J K Millar; K L Evans; S Le Hellard; A Condie; W J Muir; D H R Blackwood; D J Porteous Journal: Mol Psychiatry Date: 2005-07 Impact factor: 15.992
Authors: K E Borgmann-Winter; N E Rawson; H-Y Wang; H Wang; M L Macdonald; M H Ozdener; K K Yee; G Gomez; J Xu; B Bryant; G Adamek; N Mirza; E Pribitkin; C-G Hahn Journal: Neuroscience Date: 2008-10-17 Impact factor: 3.590
Authors: Dong-Jing Zou; Alexander T Chesler; Claire E Le Pichon; Andriy Kuznetsov; Xin Pei; Eugene L Hwang; Stuart Firestein Journal: J Neurosci Date: 2007-06-20 Impact factor: 6.167
Authors: N C Andreasen; M A Wilcox; B-C Ho; E Epping; S Ziebell; E Zeien; B Weiss; T Wassink Journal: Mol Psychiatry Date: 2011-08-30 Impact factor: 15.992
Authors: Jürgen Kayser; Craig E Tenke; Christopher J Kroppmann; Daniel M Alschuler; Shelly Ben-David; Shiva Fekri; Gerard E Bruder; Cheryl M Corcoran Journal: Int J Psychophysiol Date: 2013-07-13 Impact factor: 2.997
Authors: David R Roalf; Megan Quarmley; Monica E Calkins; Theodore D Satterthwaite; Kosha Ruparel; Mark A Elliott; Tyler M Moore; Ruben C Gur; Raquel E Gur; Paul J Moberg; Bruce I Turetsky Journal: Schizophr Bull Date: 2017-05-01 Impact factor: 9.306
Authors: Sunny X Tang; Paul J Moberg; James J Yi; Andrew S Wiemken; Erich M Dress; Tyler M Moore; Monica E Calkins; Donna M McDonald-McGinn; Elaine H Zackai; Beverly S Emanuel; Ruben C Gur; Raquel E Gur; Bruce I Turetsky Journal: Schizophr Res Date: 2018-07-11 Impact factor: 4.939
Authors: Bruce I Turetsky; Paul J Moberg; Megan Quarmley; Erich Dress; Monica E Calkins; Kosha Ruparel; Karthik Prabhakaran; Raquel E Gur; David R Roalf Journal: Schizophr Res Date: 2017-09-30 Impact factor: 4.939